EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent advancements in mechanistic research, therapeutic potential, and structure-activity relationships of aurora kinase inhibitors in cancer therapies

Ghanshyam Teli, Lalmohan Maji, Rohit Pal, Neelesh Maheshwari, Gurubasavaraja Swamy Purawarga Matada, Pooja A Chawla, Viney Chawla

Bioorganic Chemistry · 2025

DOI: 10.1016/j.bioorg.2024.107976 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Ghanshyam Teli und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sangam University, NH-79, Atoon, Bhilwara, 311001, Rajasthan, India; University Institute of Pharmaceutical Sciences and Research…. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 97 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aurora kinases (AURKs)-a family of serine/threonine protein kinases consisting of AURK-A, AURK-B, and AURK-C, are critical regulators of chromosomal segregation, centrosome maturation, and cytokinesis during the cell cycle. Each kinase is activated via phosphorylation at unique threonine residues: Thr288 (AURK-A), Thr232 (AURK-B), and Thr195 (AURK-C). Activation of AURK-A and AURK-B through phosphorylation triggers a series of downstream signaling pathways, including RalA, NF-κB, p53, PLK1, BRCA1/BRCA2, H2AX, and Kif2C, as well as multiple transmembrane kinase receptors. Dysregulation of these pathways has been implicated in cancer development and progression, positioning AURKs as pivotal targets for anticancer drug research. Inhibition of AURKs has demonstrated significant efficacy in tumor growth suppression and induction of cancer cell death, thereby focusing recent research on the development of potent AURK inhibitors. This review provides an in-depth exploration of AURK inhibitors, discussing their biological activities, structure-activity relationships, selectivity profiles, and mechanisms of action. Notably, compounds 6, 27, and 16 exhibit potent AURK-A inhibition with IC50 values of 1.7 nM, 11.83 nM, and 15 nM, respectively. Similarly, compounds 28, 16, and 7 demonstrate strong AURK-B inhibitory activity, with IC50 values of 10.5 nM, 12 nM, and 14.09 nM, respectively. This comprehensive overview aims to support medicinal chemists in developing more potent, selective, and safe AURK inhibitors as potential anticancer therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsAntineoplastic AgentsNeoplasmsHumansStructure-Activity RelationshipMolecular StructureAurora KinasesAnimalsDrug Screening Assays, Antitumor

Stichwörter der Autor:innen

Anticancer agentsAurora kinasesHeterocyclic scaffoldsStructure–activity relationships

Substanzen

Protein Kinase InhibitorsAntineoplastic AgentsAurora Kinases

Autor:innen und Institutionen

  • School of Pharmacy, Sangam University, NH-79, Atoon, Bhilwara, 311001, Rajasthan, India; University Institute of Pharmaceutical Sciences and Research, Baba Farid University of Health Sciences, Faridkot, Punjab 151203 In…
  • Department of Pharmaceutical Chemistry, Tarifa Memorial Institute of Pharmacy, Murshidabad, 742166, West Bengal, India.
  • Integrated Drug Discovery Centre, Department of Pharmaceutical Chemistry, Acharya & BM Reddy College of Pharmacy, Bengaluru, Karnataka, India.
  • School of Pharmacy, Sangam University, NH-79, Atoon, Bhilwara, 311001, Rajasthan, India.
  • University Institute of Pharmaceutical Sciences and Research, Baba Farid University of Health Sciences, Faridkot, Punjab 151203 India. Electronic address: pvchawla@gmail.com.
  • University Institute of Pharmaceutical Sciences and Research, Baba Farid University of Health Sciences, Faridkot, Punjab 151203 India. Electronic address: drvineychawla@gmail.com.

Zitieren

APA

Teli, G., Maji, L., Pal, R., Maheshwari, N., Purawarga Matada, G. S., Chawla, P. A., & Chawla, V. (2025). Recent advancements in mechanistic research, therapeutic potential, and structure-activity relationships of aurora kinase inhibitors in cancer therapies. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2024.107976

Vancouver

Teli G, Maji L, Pal R, Maheshwari N, Purawarga Matada GS, Chawla PA, et al. Recent advancements in mechanistic research, therapeutic potential, and structure-activity relationships of aurora kinase inhibitors in cancer therapies. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2024.107976

BibTeX
@article{Teli2025,
  author = {Teli, Ghanshyam and Maji, Lalmohan and Pal, Rohit and Maheshwari, Neelesh and Purawarga Matada, Gurubasavaraja Swamy and Chawla, Pooja A and Chawla, Viney},
  title = {Recent advancements in mechanistic research, therapeutic potential, and structure-activity relationships of aurora kinase inhibitors in cancer therapies},
  journal = {Bioorganic Chemistry},
  year = {2025},
  doi = {10.1016/j.bioorg.2024.107976}
}
Kostenlos starten →